Bicycle Therapeutics plc (BCYC)
Healthcare
- Fundamental
- 2
- Sentiment
- 3
- Technical
- 2
Do Nothing: fundamentalScore is 2 (below the required floor of 3), and the liquidity floor also fails — avgDollarVolume20 $1.49M is under the $5M minimum and the recent 3-session average of $0.82M is under the $1.5M recent-liquidity floor; neither entry type qualifies either (no momentum confirmation for a breakout stop above 3.80, and a pullback limit into the 3.42-3.47 shelf would be countertrend with price below SMA50 and MACD < 0).
Company overview
Bicycle Therapeutics plc is a clinical-stage biopharmaceutical company based in Cambridge, UK, focused on developing innovative therapies for diseases lacking effective treatments. Its leading investigational products include BT1718, BT5528, and BT8009, all in various stages of clinical trials targeting specific cancer markers. The company also explores treatments beyond oncology, such as THR-149 for diabetic macular edema, and collaborates with several biopharmaceutical entities to expand its therapeutic reach.
Fundamental
weakBicycle Therapeutics has a strong cash position but lacks recurring revenue and faces potential dilution.
Clinically interesting but commercially empty: about $470M of cash, no debt and a stated runway into 2030 are offset by effectively zero recurring revenue after every major collaboration was terminated, trailing losses near $142M, a pipeline narrowed to one Phase 2 asset and likely further dilution. The stock trades near half of cash and book value, but the weakness is in the business model rather than only in the price - a watchlist name, not a fundamental buy.
Sentiment
fairMedia and retail sentiment are indeterminate, with conflicting catalysts and no strong retail narrative.
Q3 2026 results (announced, 2026-10-29) dominate the tape — an EPS/revenue beat, an FDA orphan drug designation for the pancreatic cancer asset and runway into 2030, set against revenue that is entirely non-recurring Bayer termination catch-up and a Jefferies price-target cut issued the same day. The sentiment delta is indeterminate (fewer than three unique on-topic scored items in each window), retail is mention-only, and conflicting bullish and bearish catalysts fire the moderate red-flag flag, so the moderate red-flag cap applies.
Technical
weakThe stock is non-trending and weak-bearish, with all trend references above the current price.
Chart is weak-bearish and non-trending. The last close 3.48 sits below every trend reference — SMA20 3.65, SMA50 3.78, SMA200 4.50, EMA9 3.65, EMA21 3.67 — and below the 3.52 daily VWAP, with the 50-day under the 200-day (a declining primary trend). Momentum is soft-to-neutral: RSI14 42.30, MACD -0.03/-0.03 with a 0.00 histogram (flat, no upward thrust), ADX14 only 13.06 (no directional trend), and the sole constructive reading is Williams %R -90.41, which is a bounce-only oversold print rather than a reversal. Structure has been a persistent markdown from the March 2026 $5.7 area to the 2026-10-02 low of 3.33; the October bounce peaked at 4.14 on 2026-10-29 and has since rolled over to 3.48, back inside the lower half of the range. ATR14 0.21 is 6.03% of price. technicalScore 2. The trade plan is suppressed by hard blocks (fundamentalScore 2 < 3, plus the $5M liquidity floor failing at $1.49M avgDollarVolume20 and the recent-liquidity gate at $0.82M), so no entry structure was constructed.
You’re looking at 2026-11-06 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.

